triprolidine (OTC)

Brand and Other Names:Histex, Vanahist PD, more...Histex PD Drops, M-Hist PD, Vanaclear PD
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

oral liquid

  • 0.5mg/mL (Histex)
  • 0.625mg/mL (Vanahist PD, M-Hist PD)

Allergic Rhinitis

Indicated for temporary relief of rhinorrhea, sneezing, itchy nose, throat, or eyes owing to have fever or other upper respiratory allergies or allergic rhinitis

Histex: 2.5 mg (5 mL) PO q6hr

Vanahist PD or M-Hist PD: 2.5 mg (4 mL) PO q6hr

Dosage Forms & Strengths

oral liquid

  • 0.5mg/mL (Histex)
  • 0.625mg/mL (Vanahist PD, M-Hist PD)
  • 0.938mg/mL (Histex PD Drops)
  • 0.313mg/mL (Vanaclear PD)

Allergic Rhinitis

Indicated for temporary relief of rhinorrhea, sneezing, itchy nose, throat, or eyes owing to have fever or other upper respiratory allergies or allergic rhinitis

Histex

  • <6 years: As directed by physician
  • 6 to <12 years: 1.25 mg (2.5 mL) PO q6hr prn
  • ≥12 years: 2.5 mg (5 mL) PO q6hr

Vanahist PD or M-Hist PD

  • <6 years: As directed by physician
  • 6 to <12 years: 1.25 mg (2 mL) PO q6hr prn
  • ≥12 years: 2.5 mg (4 mL) PO q6hr

Histex PD Drops

  • 4 month to <2 years: 0.313 mg (0.33 mL) PO q4-6 hr; not to exceed 4 doses (1.33 mL) per 24 hr
  • 2 to <4 years: 0.626 mg (0.67 mL) PO q4-6 hr; not to exceed 4 doses (2.67 mL) per 24 hr
  • 4 to <6 years: 0.938 mg (1 mL) PO q4-6 hr; not to exceed 4 doses (4 mL) per 24 hr

Vanaclear PD

  • 4 month to <2 years: 0.313 mg (1 mL) PO q4-6 hr; not to exceed 4 doses (4 mL) per 24 hr
  • 2 to <4 years: 0.626 mg (2 mL) PO q4-6 hr; not to exceed 4 doses (8 mL) per 24 hr
  • 4 to <6 years: 0.938 mg (3 mL) PO q4-6 hr; not to exceed 4 doses (12 mL) per 24 hr
Next:

Interactions

Interaction Checker

and triprolidine

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            Frequency Not Defined

            Blurred vision

            Sedation

            Urinary retention

            Constipation

            Xerostomia

            Previous
            Next:

            Warnings

            Contraindications

            Patients taking sedatives or tranquilizers

            Hypersensitivity; note that cross allergenicity may occur between chemically similar antihistamines

            Cautions

            May cause CNS depression, resulting in impaired physical or mental abilities; caution patients about performing tasks that require mental alertness (eg, driving, operating machinery)

            Antihistamines may cause excitation in young children

            Discontinue and contact physician if symptoms persist beyond 7 days or are accompanied by fever

            Discontinue and contact physician if nervousness, dizziness, or sleeplessness occur

            Do not exceed recommended dose

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy

            Limited data exist

            Generally, antihistamines are considered low risk during pregnancy; however, exposure near birth of premature infants was associated with increased risk of retrolental fibroplasia

            Lactation

            Distributed in human breast milk; small, occasional doses are not expected to cause adverse effects in infant

            Larger doses may cause irritability or colicky symptoms in infant or decrease milk production in mother; nonsedating antihistamines are preferred during breastfeeding

            Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition

            Pregnancy Categories

            A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA: Information not available.

            Previous
            Next:

            Pharmacology

            Mechanism of Action

            First generation histamine-1 receptor antagonist

            Pharmacokinetics

            Peak plasma time: 1.5-2 hr

            Peak plasma concentration: 5.5-6 ng/mL

            Onset: 15-60 min

            Duration: 4-6 hr

            Half-life: 3.2 hr

            Previous
            Next:

            Administration

            Oral Administration

            Do not exceed 4 doses in 24 hr or as directed by physician

            Administer only with enclosed dropper or measuring device supplied with specific product

            Do not use the dropper or measuring device for other drug products

            Storage

            Store at controlled room temperature 15-30°C (59-86°F)

            Previous
            Next:

            Images

            Previous
            Next:
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.